Evidence map›Paper›PMID 34075644›Full record

Trial reportThe American journal on addictions2021

Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.

Marc Fishman, Kevin Wenzel, Jennifer Scodes, Martina Pavlicova, Aimee N C Campbell, John Rotrosen, Edward Nunes

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal on addictions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marc FishmanMountain Manor Treatment Center/Maryland Treatment Centers, Baltimore, Maryland.ORCID 0000-0001-6764-6410
Kevin WenzelMountain Manor Treatment Center/Maryland Treatment Centers, Baltimore, Maryland.ORCID 0000-0002-6299-7569
Jennifer ScodesDivision of Mental Health Data Science, New York State Psychiatric Institute, New York, New York.
Martina PavlicovaDepartment of Biostatistics, Columbia University Mailman School of Public Health, New York, New York.
Aimee N C CampbellDepartment of Psychiatry, Columbia University Irving Medical Center, Columbia University Medical Center, New York State Psychiatric Institute, New York, New York.ORCID 0000-0003-4247-9980
John RotrosenDepartment of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York.
Edward NunesDepartment of Psychiatry, Columbia University Irving Medical Center, Columbia University Medical Center, New York State Psychiatric Institute, New York, New York.ORCID 0000-0002-2055-3425

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
National Center on Integrative and Complimentary Health AT010614NCCIH NIH HHS R61 AT010614NIDA NIH HHS T32 DA037801NIDA NIH HHS U10 DA013034NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013046NIDA NIH HHS U10DA013046NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA015833NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1/U10DA013034NIDA NIH HHS UG1/ U10DA013035
6 · The paper itself

Abstract

BACKGROUND AND

objectivesOpioid use disorder (OUD) treatment outcomes are poorer for young adults than older adults. Developmental differences are broadly implicated, but particular vulnerability factor interactions are poorly understood. This study sought to identify moderators of OUD relapse between age groups.

methodsThis secondary analysis compared young adults (18-25) to older adults (26+) from a comparative effectiveness trial ("XBOT") that randomized (N = 570) participants to extended-release naltrexone or sublingual buprenorphine-naloxone. We explored the relationship between 25 prespecified patient baseline characteristics and relapse to regular opioid use by age group and treatment condition, using logistic regression.

resultsYoung adults (n = 111) had higher rates of 24-week relapse than older adults (n = 459) (70.3% vs 58.8%) and differed on a number of specific characteristics, including more smokers, more intravenous opioid use, and more cannabis use. No significant moderators predicted relapse, in either three-way or two-way interactions. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: No baseline factors were identified as moderating the relationship between age group and opioid relapse, nor any interactions between baseline characteristics, age group, and treatment condition to predict opioid relapse. Poorer treatment outcomes for young adults are likely associated with multiple developmental vulnerabilities rather than any single predominant factor. Although not reaching significance, several characteristics (using heroin, smoking tobacco, high levels of depression/anxiety, or treatment because of family/friends) showed higher odds ratio point estimates for relapse in young adults than older adults. This is the first study to explore moderators of worse OUD treatment outcomes in young adults, highlighting the need to identify predictor variables that could inform treatment enhancements. (Am J Addict 2021;00:1-12).

Indexed as

Buprenorphine, Naloxone Drug CombinationOpioid-Related DisordersAgedAnalgesics, OpioidDelayed-Action PreparationsHumansNaltrexoneOpiate Substitution TreatmentYoung AdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsNaltrexone

Identifiers

PMID34075644
PMCPMC8429062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.